A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV.

During the past decade, successful gene therapies for immunodeficiencies were finally brought to the clinic. This was accomplished through new gene therapy vectors and improved procedures for genetic modification of autologous hematopoietic stem cells. For HIV, autologous hematopoietic stem cell (HSC) gene therapy with 'anti-HIV genes' promises a functional cure for the disease. However, to develop such a therapy and translate it into a clinical application is rather challenging. The risks and benefits of such a therapy have to be understood, and regulatory hurdles need to be overcome. In this joint paper by academic researchers and regulators, we are, therefore, outlining a high level roadmap for the early stage development of HSC gene therapy as a potential functional cure for HIV.

[1]  S. Cohn,et al.  The Black Death and AIDS: CCR5-Δ32 in genetics and history , 2006 .

[2]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[3]  J. Arcidiacono,et al.  US Food and Drug Administration international collaborations for cellular therapy product regulation , 2012, Stem Cell Research & Therapy.

[4]  J. Zaia,et al.  Practical Considerations in Gene Therapy for HIV Cure , 2014, Current HIV/AIDS Reports.

[5]  Nina M. Muñoz,et al.  Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model after In Vivo Selection , 2009, PloS one.

[6]  D. Barouch.  The quest for an HIV-1 vaccine--moving forward. , 2013, The New England journal of medicine.

[7]  G. Bauer,et al.  Fighting HIV with stem cell therapy: one step closer to human trials? , 2012, Expert review of anti-infective therapy.

[8]  Shiu-Lok Hu,et al.  Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. , 2013, Blood.

[9]  Kathryn L. Parsley,et al.  Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency , 2011, Science Translational Medicine.

[10]  B. Berkhout,et al.  HIV-1-based lentiviral vectors. , 2014, Methods in molecular biology.

[11]  D. Kohn,et al.  Gene transfer into human umbilical cord blood-derived CD34+ cells by particle-mediated gene transfer , 1998, Gene Therapy.

[12]  Aaron R Cooper,et al.  Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. , 2012, Blood.

[13]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[14]  Andrew Buchanan,et al.  Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  R. Pollard,et al.  Generation of an HIV-1-Resistant Immune System with CD34+ Hematopoietic Stem Cells Transduced with a Triple-Combination Anti-HIV Lentiviral Vector , 2012, Journal of Virology.

[16]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[17]  E. Thiel,et al.  Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. , 2011, Blood.

[18]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[19]  M. Budoff,et al.  HIV infection and the risk of acute myocardial infarction. , 2013, JAMA internal medicine.

[20]  A. Statnikov,et al.  Strategic Applications of Gene Expression: From Drug Discovery/Development to Bedside , 2013, The AAPS Journal.

[21]  G. Cossu,et al.  The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis. , 2013, Human gene therapy. Clinical development.

[22]  Emily B Hanhauser,et al.  Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation , 2014, Annals of Internal Medicine.

[23]  H. Günthard,et al.  Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption , 2011, PloS one.

[24]  Alessandro Marcello,et al.  HIV-1 transcription and latency: an update , 2013, Retrovirology.

[25]  Kenneth L. Schaecher,et al.  The importance of treatment adherence in HIV. , 2013, The American journal of managed care.

[26]  J. Nolta,et al.  Specific Transduction of HIV-Susceptible Cells for CCR5 Knockdown and Resistance to HIV Infection: A Novel Method for Targeted Gene Therapy and Intracellular Immunization , 2009, Journal of acquired immune deficiency syndromes.

[27]  Xiuli Wang,et al.  In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  A. Krishnan,et al.  Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice , 2013, Viruses.

[29]  S. Cole,et al.  Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. , 2004, Human gene therapy.

[30]  S. Karlsson,et al.  Efficient Characterization of Retro‐, Lenti‐, and Foamyvector‐Transduced Cell Populations by High‐Accuracy Insertion Site Sequencing , 2003, Annals of the New York Academy of Sciences.

[31]  I. Müller,et al.  Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[33]  M. Kay.  State-of-the-art gene-based therapies: the road ahead , 2011, Nature Reviews Genetics.

[34]  J. Montaner,et al.  Adverse effects of antiretroviral therapy for HIV infection. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[35]  BattiwallaMinoo,et al.  Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. , 2014 .

[36]  C. Salata,et al.  A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. , 1999, Blood.

[37]  Kathryn L. Parsley,et al.  Immunodeficiency: Long-term persistence of a polyclonal t cell repertoire after gene therapy for X-linked severe combined immunodeficiency , 2011 .

[38]  J. Rasko,et al.  Clinical potential of gene therapy: towards meeting the demand , 2014, Internal medicine journal.

[39]  D. Williams,et al.  Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection , 2011, Gene Therapy.

[40]  H. Heslop,et al.  Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). , 2006, Blood.

[41]  R. Akkina,et al.  Gene Therapy Strategies for HIV/AIDS: Preclinical Modeling in Humanized Mice , 2013, Viruses.

[42]  M. Carr,et al.  Regulatory structures for gene therapy medicinal products in the European Union. , 2012, Methods in enzymology.

[43]  J. Nolta,et al.  CD25 preselective anti-HIV vectors for improved HIV gene therapy. , 2012, Human gene therapy methods.

[44]  Y. Durocher,et al.  Development of a scalable process for high‐yield lentiviral vector production by transient transfection of HEK293 suspension cultures , 2009, The journal of gene medicine.

[45]  W. Bryan,et al.  The state of gene therapies: the FDA perspective. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  J. O'donnell.  Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[47]  R. Hawley,et al.  Overview of the HIV‐1 Lentiviral Vector System , 2002, Current protocols in molecular biology.

[48]  L. Gostin,et al.  Oversight and Review of Clinical Gene Transfer Protocols , 2014 .

[49]  H Clifford Lane,et al.  Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. , 2005, Human gene therapy.

[50]  R. Maziarz,et al.  Hematopoietic stem cell transplantation and implications for cell therapy reimbursement. , 2011, Cell stem cell.

[51]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[52]  Brian Fury,et al.  Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  F. Candotti.  Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases , 2014, International Journal of Hematology.

[54]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.

[55]  Hans-Peter Kiem,et al.  Hematopoietic-stem-cell-based gene therapy for HIV disease. , 2012, Cell stem cell.

[56]  Daniel Kaiser,et al.  Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. , 2013, Cytotherapy.

[57]  Frederic D. Bushman,et al.  Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.

[58]  G. Bauer,et al.  Stem cell transplantation in the context of HIV – how can we cure HIV infection? , 2014, Expert review of clinical immunology.

[59]  H. Volk,et al.  Adoptive T‐Cell Therapy of a Lung Transplanted Patient with Severe CMV Disease and Resistance to Antiviral Therapy , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[60]  A. LaCasce,et al.  Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. , 2013, The Journal of infectious diseases.

[61]  Robert Zorec,et al.  Challenges with advanced therapy medicinal products and how to meet them , 2010, Nature Reviews Drug Discovery.

[62]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.